Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein-Tyrosine Kinase 7 (PTK7), also known as colon carcinoma kinase 4 (CCK4), is a single-pass transmembrane receptor belonging to the receptor tyrosine kinase (RTK) family. Despite its classification, PTK7 is an atypical or "defective" RTK because it lacks intrinsic catalytic tyrosine kinase activity in its intracellular domain. It is involved primarily in developmental processes via modulation of Wnt signaling pathways, and its aberrant expression contributes to carcinogenesis, making it an attractive target for novel anti-cancer therapies.
Antibody-drug conjugates targeting PTK7
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein-Tyrosine Kinase 7 (PTK7).